Lv73
3560 积分 2023-09-18 加入
Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study
5天前
已完结
Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
5天前
已完结
Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation
12天前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
1个月前
已完结
Survival Benefit of Combined Systemic and Locoregional Therapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score-Matched Analysis
3个月前
已关闭
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
3个月前
已完结
Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial
4个月前
已完结
Adjuvant lenvatinib in combination with transarterial chemoembolization for hepatocellular carcinoma patients with high risk of postoperative recurrence: A multicenter prospective cohort study
4个月前
已完结
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma
5个月前
已完结
皖公网安备34019202002308
